US2005239856A1PendingUtilityA1

Method for prophylaxis and treatment of diabetic complications with 4{alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl}-3,5-dimethylbenzoic acid and derivatives

53
Assignee: HAYASHI YOSHIHARUPriority: Dec 27, 1995Filed: Jun 15, 2005Published: Oct 27, 2005
Est. expiryDec 27, 2015(expired)· nominal 20-yr term from priority
Inventors:Yoshiharu HayashiNobuharu Goto
A61P 9/00A61P 3/10A61P 3/00A61P 25/00A61P 27/00A61P 25/02A61P 13/00C07D 233/56C07D 249/08A61K 31/4164C07D 233/54C07D 231/12A61K 31/415C07D 233/60
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to an agent for the prophylaxis and treatment of diabetic complications comprising, as an active ingredient, 4-[α-hydroxy-2-methyl-5(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for the prophylaxis and treatment of diabetic complications comprising administering an effective amount of this compound. The medicament of the present invention is useful for the prophylaxis and treatment of diabetic complications, namely, diabetic neuropathy, nephropathy, ophthalmopathy, arteriosclerosis and the like. The action of the drug is long-lasting for very small doses and a single administration a day is sufficient.

Claims

exact text as granted — not AI-modified
1 . A method for the prophylaxis and treatment of diabetic ophthalmopathy, comprising administering an effective amount of 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof.  
   
   
       2 . A method for the prophylaxis and treatment of diabetic ophthalmopathy, comprising administering an effective amount of sodium 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate dihydrate.  
   
   
       3 . A method for the prophylaxis and treatment of diabetic ophthalmopathy, comprising administering an effective amount of (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid or a pharmaceutically acceptable salt thereof.  
   
   
       4 . A method for the prophylaxis and treatment of diabetic ophthalmopathy, comprising administering an effective amount of sodium (S)-(−)- 4 -[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate 2/3 hydrate.  
   
   
       5 . A method for the prophylaxis and treatment of diabetic arteriosclerosis, comprising administering an effective amount of 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof.  
   
   
       6 . A method for the prophylaxis and treatment of diabetic arteriosclerosis, comprising administering an effective amount of sodium 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate dihydrate.  
   
   
       7 . A method for the prophylaxis and treatment of diabetic arteriosclerosis, comprising administering an effective amount of (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid or a pharmaceutically acceptable salt thereof.  
   
   
       8 . A method for the prophylaxis and treatment of diabetic arteriosclerosis, comprising administering an effective amount of sodium (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate 2/3 hydrate.  
   
   
       9 . The method of  claim 1 , wherein the diabetic ophthalmopathy is cataract.  
   
   
       10 . The method of  claim 1 , wherein the diabetic ophthalmopathy is glaucoma.  
   
   
       11 . The method of  claim 1 , wherein the diabetic ophthalmopathy is retinopathy.  
   
   
       12 . The method of  claim 1 , wherein the diabetic ophthalmopathy is iritis.  
   
   
       13 . The method of  claim 2 , wherein the diabetic ophthalmopathy is cataract.  
   
   
       14 . The method of  claim 2 , wherein the diabetic ophthalmopathy is glaucoma.  
   
   
       15 . The method of  claim 2 , wherein the diabetic ophthalmopathy is retinopathy.  
   
   
       16 . The method of  claim 2 , wherein the diabetic ophthalmopathy is iritis.  
   
   
       17 . The method of  claim 3 , wherein the diabetic ophthalmopathy is cataract.  
   
   
       18 . The method of  claim 3 , wherein the diabetic ophthalmopathy is glaucoma.  
   
   
       19 . The method of  claim 3 , wherein the diabetic ophthalmopathy is retinopathy.  
   
   
       20 . The method of  claim 3 , wherein the diabetic ophthalmopathy is iritis.  
   
   
       21 . The method of  claim 4 , wherein the diabetic ophthalmopathy is cataract.  
   
   
       22 . The method of  claim 4 , wherein the diabetic ophthalmopathy is glaucoma.  
   
   
       23 . The method of  claim 4 , wherein the diabetic ophthalmopathy is retinopathy.  
   
   
       24 . The method of  claim 4 , wherein the diabetic ophthalmopathy is iritis.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.